MorphoSys AG
XETRA:MOR

Watchlist Manager
MorphoSys AG Logo
MorphoSys AG
XETRA:MOR
Watchlist
Price: 67.25 EUR 0.37%
Market Cap: 2.5B EUR
Have any thoughts about
MorphoSys AG?
Write Note

Net Margin
MorphoSys AG

-226.2%
Current
-157%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-226.2%
=
Net Income
-460.3m
/
Revenue
203.5m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
DE
MorphoSys AG
XETRA:MOR
2.5B EUR
-226%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country DE
Market Cap 2.5B EUR
Net Margin
-226%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 315.2B USD
Net Margin
9%
Country US
Market Cap 141.9B USD
Net Margin
13%
Country US
Market Cap 116.4B USD
Net Margin
0%
Country US
Market Cap 104.5B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 78.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

MorphoSys AG
Glance View

Market Cap
2.5B EUR
Industry
Biotechnology

MorphoSys AG emerged from the vibrant biotechnology landscape of Munich, Germany, in 1992. It was founded on the innovative idea of harnessing antibodies as a means to combat diseases. With a precision-driven approach to drug development, MorphoSys primarily concentrates on creating and bringing to market therapeutic agents for cancer and inflammatory disorders. Taking center stage is their proprietary technology platform that enables the discovery of monoclonal antibodies, pivotal in the fight against these daunting ailments. This platform not only serves their internal pipeline but also provides a significant source of revenue through collaborations and licensing agreements with major pharmaceutical giants, enabling MorphoSys to strike timely alliances that bolster both innovation and profitability. Central to MorphoSys's business model is its dual focus: advancing its own pipeline of antibody-based therapeutics while simultaneously offering its technological platforms to partners. This symbiosis allows the company to generate revenue through milestone payments and royalties as partnered drugs advance through clinical trials and into the market. A key asset in its lineup is Monjuvi, a groundbreaking treatment for lymphoma, which underscores the firm's capability to evolve from tech-driven operations to delivering market-ready solutions. As markets grow increasingly competitive, MorphoSys's strategic prowess lies in balancing its R&D investments with collaborative ventures, ensuring a steady revenue stream and a robust presence in the biopharmaceutical realm.

MOR Intrinsic Value
34.16 EUR
Overvaluation 49%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-226.2%
=
Net Income
-460.3m
/
Revenue
203.5m
What is the Net Margin of MorphoSys AG?

Based on MorphoSys AG's most recent financial statements, the company has Net Margin of -226.2%.